20537 ⎘
Medicinal preparations containing organic active ingredients; Carbohydrates; Sugars; Derivatives thereof; Compounds having three or more nucleosides or nucleotides Double-stranded nucleic acids or oligonucleotides
Methods and compositions for treatment of atherosclerosis
#2102Compositions and methods for inhibiting cancer stem cells
#2103APPARATUS AND METHODS FOR MAKING NANOSOMES LOADED WITH NUCLEIC ACID
#2104METHODS AND PRODUCTS FOR NUCLEIC ACID PRODUCTION AND DELIVERY
#2105Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
#2106Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
#2107METHODS FOR TREATING AND/OR PREVENTING A TUMOR GROWTH, INVASION AND/OR METASTASIS
#2108RAAV-BASED COMPOSITIONS AND METHODS
#2109Method effective to modulate expression of T-box protein 4 (Tbx4) for reducing progression of lung fibrosis after a lung injury
#2110Motor neuron-specific expression vectors
#2111Thymidine kinase diagnostic assay for gene therapy applications
#2112Method for treating a degenerative neurological disorders comprising administering ASM inhibitor
#2113Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung
#2114METHODS FOR THE TREATMENT OF ALOPECIA AREATA UTILIZING GENE MODULATION APPROACHES
#2115ENCAPSULATION OF MESSENGER RNA
#2116Pharmaceutical composition for treating or preventing obesity
#2117Compounds for inducing anti-tumor immunity and methods thereof
#2118Compositions and methods for modulating FMR1 expression
#2119Toxicity management for anti-tumor activity of CARs
#2120Method for identification of anti-HIV human miRNA mimics and miRNA inhibitors and anti-HIV pharmaceutical compounds
#2121Non-silencing selectable marker genes and methods of use
#2122Compositions and Methods for Inducing Senescence in Cancer Cells
#2123Use of trinucleotide repeat RNAs to treat cancer
#2124Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
#2125MODIFIED POLY (BETA-AMINO ESTER)S FOR DRUG DELIVERY
#2126Compositions and methods for inhibiting expression of ADAMTS-5 and ADAM17
#2127Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them
#2128Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
#2129Nanoparticle conjugates and uses thereof
#2130Compounds and methods for trans-membrane delivery of molecules
#2131Toxicity management for anti-tumor activity of CARs
#2132Methods and compositions for eliciting an immune response against hepatitis B virus
#2133Inhibitor of IGFBP3/TMEM219 axis and diabetes
#2134Anti-cancer agent comprising HVJ-E and CXCL2
#2135Method of treating severe asthma
#2136Notch 1 specific siRNA molecule
#2137Methods and compositions of short small hairpin RNAS and microRNAS for wound healing
#2138Thymidine kinase gene
#2139Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis
#2140IRGM and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
#2141Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
#2142RNA INTERFERENCE THERAPEUTICS AGAINST EBOLA VIRUS
#2143Methods of identifying and treating poor-prognosis cancers
#2144Compositions and methods for inhibiting gene expression of Hif2alpha
#2145Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#2146BROADLY NEUTRALIZING HUMAN ANTIBODY THAT RECOGNIZES THE RECEPTOR-BINDING POCKET OF INFLUENZA HEMAGGLUTININ
#2147INHIBITION OF CXCR4 SIGNALING IN CANCER IMMUNOTHERAPY
#2148Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
#2149METHOD OF TREATING AND PROGNOSING SCOLIOTIC PATIENT SUBGROUPS
#2150Modulation of TMPRSS6 expression
#2151Interfering RNA molecules
#2152Multimeric oligonucleotides having decreased kidney clearance
#2153Structurally-enhanced miRNA inhibitor S-TuD
#2154Ionizable cationic lipid for RNA delivery
#2155METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS
#2156Agents for use in the treatment of glioma
#2157Treatments of oxidative stress conditions
#2158Sterile formulation comprising a stable phosphorothioate oligonucleotide
#2159COMPOSITIONS AND METHODS FOR TREATING FIBROSING DISORDERS AND CANCER
#2160Compositions and methods for modulating ABHD2 activity
#2161Compositions and methods for inhibiting expression of the PCSK9 gene
#2162XANTHINE DEHYDROGENASE (XDH) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#2163HSD17B13 variants and uses thereof
#2164Non-alcoholic fatty liver regulator 14-3-3 protein
#2165Modified siRNA and pharmaceutical composition
#2166MODULATION OF SRPX2-MEDIATED ANGIOGENESIS
#2167Methods and compositions for selecting siRNA of improved functionality
#2168SPHERICAL NUCLEIC ACID (SNA)-MEDIATED DELIVERY OF LIPID-COMPLEXES TO CELLS
#2169METHOD FOR INDIVIDUALIZED CANCER THERAPY
#2170Modulation of hepatitis B virus replication
#2171Epigeneiic silencing of NMT2
#2172COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS B VIRUS GENE EXPRESSION
#2173TREATMENT OF LIPID TRANSPORT AND METABOLISM GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A LIPID TRANSPORT AND METABOLISM GENE
#2174Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#2175LENTIVIRUS AND NON-INTEGRATING LENTIVIRUS AS VIRAL VECTOR TO DELIVER CRISPR THERAPEUTIC
#2176Cationic lipids for therapeutic agent delivery formulations
#2177INHIBITION OF CANCER GROWTH AND METASTASIS
#2178COMPOSITIONS AND METHODS FOR IMPROVING ENZYME REPLACEMENT THERAPY FOR LYSOSOMAL STORAGE DISEASES
#2179SUBSTANCE AND METHOD FOR MODULATING PROLIFERATION AND DIFFERENTIATION OF REGULATORY, STEM AND OTHER SOMATIC CELLS
#2180Nanoparticles containing extracellular matrix for drug delivery
#2181Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
#2182Methods and compositions for treating cancers using antisense
#2183Methods of treating pain using anti-GPR160 antibodies
#2184Fidgetin-like 2 as a target to enhance wound healing
#2185Methods and compositions for selecting siRNA of improved functionality
#2186Compounds for inducing anti-tumor immunity and methods thereof
#2187Albumin production and cell proliferation
#2188Micromirs
#2189Isolated antibodies against interleukin-17 receptor B (IL-17RB) for cancer therapy
#2190Pharmaceutical composition for inhibiting resistance against anticancer drugs of patient suffering from ovarian cancer comprising NAG-1 inhibitor as active ingredient
#21912'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS
#2192Control of coleopteran pests using RNA molecules
#2193COMPOSITIONS AND METHODS FOR TREATING LUNG DISEASES AND LUNG INJURY
#2194Glucokinase (GCK) iRNA compositions and methods of use thereof
#2195Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
#2196RNA interference mediated inhibition of hepatitis B Virus (HBV) gene expression using short interfering nucleic acid (siNA)
#2197Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
#2198Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
#2199Transgenic microalgae and use thereof as a feed for delivery of interfering RNA molecules
#2200DISCONTINUOUS OLIGONUCLEOTIDE LIGANDS
#2201ß2GPI GENE EXPRESSION-SUPPRESSING NUCLEIC ACID CONJUGATE
#2202Micro-RNA for the treatment of malignant solid tumors and metastasis
#2203Immunostimulating oligonucleotide complex
#2204Diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery
#2205EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS
#2206Fusogenic liposome-coated porous silicon nanoparticles
#2207NANOLIPOSOMAL FORMULATION FOR TARGETING INTEGRIN-LINKED KINASE (ILK) WITH SMALL-INTERFERENCE RNA AND A METHOD FOR TREATING OVARIAN CANCER
#2208MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY CONDITIONS
#2209Inhibitors of DEK protein and related methods
#2210Cancer specific-splicing ribozyme and use thereof
#2211Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
#2212Treatment for myopathy
#2213METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING LYMPHOCYTE PROLIFERATION IN A SUBJECT IN NEED THEREOF
#2214Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
#2215Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
#2216Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
#2217Modified L-Nucleic Acid
#2218ANTISENSE NUCLEIC ACIDS
#2219Modulation of BCL11A for treatment of hemoglobinopathies
#2220Multicomponent Degradable Cationic Polymers
#2221COMPOSITIONS AND METHODS FOR MODULATING PRO-INFLAMMATORY IMMUNE RESPONSE
#2222miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers
#2223Combination therapies for the treatment of Alzheimer's disease and related disorders
#2224Combination therapies for the treatment of Alzheimer's disease and related disorders
#2225Combination therapies for the treatment of Alzheimer'S disease and related disorders
#2226Selective reduction of the deleterious activity of extended tri-nucleotide repeat containing genes
#2227Targeting microRNAs for metabolic disorders
#2228siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
#2229Use of phospholipid scramblase inhibitors for modulating inflammatory immune responses
#2230DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS
#2231Method of Increasing GIPCR Signalization in the Cells of a Scoliotic Subject
#2232Carrier nanoparticles and related compositions, methods and systems
#2233Allele specific modulators of P23H rhodopsin
#2234Dual assembly nanoparticles
#2235Methods for treatment of metastatic thyroid cancer using a PDGFR-α inhibitor
#2236Sortilin 1 is a novel inducer of vascular calcification
#2237Method for treatment of subjects with TUG1 gene expressing brain tumor
#2238Micro-RNA family that modulates extracellular matrix genes and uses thereof
#2239Compositions and methods for transport across the blood brain barrier
#2240Antibody-SN-38 immunoconjugates with a CL2A linker
#2241Compositions and methods for treating cancer
#2242CITRIN INHIBITORS FOR THE TREATMENT OF CANCER
#2243Materials and methods for modulation of tendon healing
#2244Cationic lipid
#2245Cationic polymer coated mesoporous silica nanoparticles and uses thereof
#2246DNA vaccine against amyloid-β and tau
#2247UNIT STRUCTURE-TYPE PHARMACEUTICAL COMPOSITION FOR NUCLEIC ACID DELIVERY
#2248ORGANIC COMPOSITIONS TO TREAT KRAS-RELATED DISEASES
#2249Diagnosis and treatment of MERS-related renal disease
#2250CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF
#2251RNAi inhibition of alpha-ENaC expression
#2252UNA oligomers and compositions for treating amyloidosis
#2253Dual Targeting siRNA Agents
#2254Compositions and methods for delivery of agents
#2255CARBON MATERIAL DELIVERY SYSTEMS AND METHODS
#2256Amorphous metal-organic frameworks
#2257Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone-associated medical conditions
#2258Combination therapy using PDK1 and PI3K inhibitors
#2259METHOD FOR TREATMENT AND PROGNOSIS OF COLORECTAL CANCER
#2260COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL
#2261Benzene-1,3,5-tricarboxamide derivatives and uses thereof
#2262Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes
#2263Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
#2264Methods and compositions for the treatment of cancer or other diseases
#2265Oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and application thereof
#2266Oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and application thereof
#2267Methods and pharmaceutical compositions for treating peripheral demyelinating diseases
#2268Unimolecular nanoparticles for efficient delivery of therapeutic RNA
#2269Therapeutic oligomers for treating amyloidosis
#2270Oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and application thereof
#2271Stabilized STAT3 decoy oligonucleotides and uses therefor
#2272Treatment of CNS Disorders Associated with Mutations in Genes Encoding Lysosomal Enzymes
#2273Therapeutics targeting IGFBP7 for the treatment or prevention of heart failure and metabolic diseases
#2274DENDRITIC CELL IMMUNOTHERAPY
#2275Lipids and compositions for the delivery of therapeutics
#2276Immune modulation with TLR9 agonists for cancer treatment
#2277Compositions and methods for detecting proteinopathies
#2278Androgen receptor variant inhibitors and methods of using
#2279Methods for treating acute myeloid leukemia and nanoparticle complexes of miR-22 utilized therein
#2280Methods and compositions for selecting siRNA of improved functionality
#2281Crystals as hosts for entrapment and slow release of compounds
#2282METHODS FOR ENHANCING AN IMMUNE RESPONSE WITH A CTLA-4 ANTAGONIST
#2283MiRNA compositions for the treatment of mature B-cell neoplasms
#2284Therapy for malignant disease
#2285LncRNA serves as a biomarker and therapeutic target
#2286Delivery of hydrophobic active agent particles
#2287Method of treating androgen receptor negative prostate tumors and their metastases
#2288METHODS AND COMPOSITIONS FOR INHIBITING THE GROWTH AND/OR PROLIFERATION OF MYC-DRIVEN TUMOR CELLS
#2289Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
#2290Selective inhibitors of tumor-initiating cells
#2291Bivalent siRNA chimeras and methods of use thereof
#2292Methods for therapeutic targeting of circulating tumor cells during hemodialysis
#22932′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
#22942′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
#2295Diagnostic and screening methods for atopic dermatitis
#2296RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
#2297Organic compositions to treat EPAS1-related diseases
#2298Therapeutic gene cocktail for heart regeneration
#2299Screening method, a kit, a method of treatment and a compound for use in a method of treatement
#2300Oligonucleotide compounds for targeting huntingtin mRNA
#2301Inhibitors of MYH7B and uses thereof
#2302Lipids and compositions for the delivery of therapeutics
#2303Oligonucleotide analogues targeting human LMNA
#2304Methods used to treat cancer
#2305NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY
#2306COMPETITIVE MODULATION OF MICRORNAS
#2307Methods of treating cancer
#2308Oligonucleotide compositions with enhanced efficiency
#2309Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#2310METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BONE METASTASES
#2311Method of treating diabetic nephropathy in a subject suffering from type 2 diabetes by administering an antibody which inhibits VEGF-B signaling
#2312STING (Stimulator of Interferon Genes), A Regulator of Innate Immune Responses
#2313Polyvalent RNA-nanoparticle compositions
#2314Agents and methods for treating pancreatic ductal adenocarcinomas
#2315Methods for treating cancer with RORγ inhibitors
#2316Methods of treating ischemic organ damage and other disorders
#2317NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY
#2318CANCER MARKER AND THE USE THEREOF
#2319Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides
#2320COMPOSITIONS AND METHODS OF TREATING ACUTE MYELOID LEUKEMIA
#2321Compositions and methods for delivery of biomacromolecule agents
#2322Homologous recombination factors
#2323NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS
#2324Plasmonic nanoparticle immunoassay method
#2325Pharmaceutical composition for treating Charcot Marie Tooth disease
#2326RNA interference mediated therapy for neurodegenerative diseases
#2327p63 inactivation for the treatment of heart failure
#2328Pharmaceutical composition for preventing and teating endocrine disrupting chemicals-induced diseases and treating method using the same
#2329TARGETING TRASTUZUMAB-RESISTANT HER2+ BREAST CANCER WITH A HER3-TARGETING NANOPARTICLE
#2330Biodegradable lipids for the delivery of active agents
#2331Targeting ligands
#2332NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS
#2333Method of Vaccination Comprising a Histone Deacetylase Inhibitor
#2334Assay for telomere length regulators
#2335Liposome structures and methods of use thereof
#2336Method of Enhancing Delivery of Therapeutic Compounds to the Eye
#2337MOLECULAR TARGETS FOR THE PREVENTION AND/OR TREATMENT OF FIBROSIS, HYPERTROPHIC SCARS OR KELOIDS
#2338Compositions and methods for inhibition of nucleic acids function
#2339Compositions and methods for nucleic acid transfer
#2340Hepcidin antagonists for use in the treatment of inflammation
#2341CANCER THERAPEUTICS
#2342Therapeutic nanoparticles and methods of use thereof
#2343Cholestosome vesicles for incorporation of molecules into chylomicrons
#2344METHODS AND USES FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
#2345Cationic lipid
#2346INHIBITORS OF MIR-17-92 CLUSTER FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA AND OTHER MALIGNANCIES
#2347PCI method for generating immune respose to antigenic molecule using checkpoint inhibitor and TLR3 ligand
#2348Preeclampsia
#2349Compositions and Methods for Treating Niemann Pick C Disease
#2350Inflammasome activation in myelodysplastic syndromes
#2351METHOD OF DIAGNOSIS, PROGNOSIS OR TREATMENT OF NEURODEGENERATIVE DISEASES
#2352Treatment of hyperhidrosis
#2353Composition for treating cancer associated with HPV infection
#2354Double-stranded ribonucleic acid for adjuvants
#2355Compositions and methods for modulating TTR expression
#2356TREATING SOLID TUMOR BY TARGETING DECTIN-1 SIGNALING
#2357Amphipathic peptide
#2358Lipids and compositions for the delivery of therapeutics
#2359Glutamate Dehydrogenase 1 Inhibitors and Methods of Treating Cancer
#2360Unit structure-type pharmaceutical composition for nucleic acid delivery
#2361NOVEL COMPOSITIONS OF COMBINATIONS OF NON-COVALENT DNA BINDING AGENTS AND ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS AND THEIR USE IN DISEASE TREATMENT
#2362METHODS OF TREATING AGE RELATED DISORDERS
#2363IMMUNO-REGULATORY LIPID CONTAINING SPHERICAL NUCLEIC ACIDS
#2364COMPOSITIONS AND METHODS FOR EFFICACIOUS AND SAFE DELIVERY OF SIRNA USING SPECIFIC CHITOSAN-BASED NANOCOMPLEXES
#2365Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
#2366Compositions and methods for inhibiting expression of the ALAS1 gene
#2367CKAP4-molecular-targeted antitumor agent
#2368METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIV INFECTION
#2369BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF
#2370COMPOSITIONS AND METHODS OF ALTERING CHOLESTEROL LEVELS
#2371Synergistic cancer treatment
#2372RNAi molecule delivery platform based on single-siRNA and shRNA nanocapsules
#2373Cell membrane-derived nanovesicles and use thereof
#2374Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability
#2375Method for improving learning
#2376Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
#2377NON-IONIC, LOW OSMOLAR CONTRAST AGENTS FOR DELIVERY OF ANTISENSE OLIGONUCLEOTIDES AND TREATMENT OF DISEASE
#2378MicroRNA therapy for pancreatic cancer
#2379Pharmaceutical composition for treating cancer comprising microrna as active ingredient
#2380Method of treating a localized fibrotic disorder using an IL-33 antagonist
#2381Methods and compositions for wound healing
#2382TARGETED NANOPARTICLES
#2383RVG Derived peptides
#2384Compositions and methods for delivery of agents
#2385COMPOSITIONS AND METHODS TO INDUCE TARGETED APOPTOSIS BY MODULATING PROTEIN TYROSINE PHOSPHATASE 13 (PTPN13)
#23862′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
#2387Anti-viral compositions containing PIKfyve inhibitors and use thereof
#2388SUSTAINED RELEASE DRUG DELIVERY DEVICES
#2389COATED CHITOSAN-BASED POLYPLEX FOR DELIVERY OF NUCLEIC ACIDS
#2390Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
#2391Peptide/particle delivery systems
#2392Screening Method For Compound Having Obesity Preventive Or Therapeutic Activity
#2393Compositions and methods for inhibiting gene expression of factor XII
#2394Long Non-Coding RNA For The Treatment Of Endothelial Dysfunction
#2395Circular RNA For The Diagnosis Of Cardiovascular And Inflammatory Diseases
#2396Compositions for modulating expression of C9ORF72 antisense transcript
#2397Biological Materials and Uses Thereof
#2398Antisense conjugates for decreasing expression of DMPK
#2399Lipid Nanoparticle Compositions and Methods of Making and Methods of Using the Same
#2400Methods and products for nucleic acid production and delivery